Skip to content
DataLookout
Menu

FORWARDNCT06010199

Clinical Phenotypes, Long-Term Outcomes, and Biobanking in Myocarditis

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 16 years 5 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jul 31, 2030 to Dec 31, 2046 Show 9 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 1000 → 5000 participants
    • Eligibility criteria expanded, about 468 words
    • Study completion pushed from Aug 31, 2030 to Dec 31, 2050
    • Trial arms changed: 1 → 2
    • Secondary endpoints: 4 to 13
    • Study description expanded, about 1,106 words
    • Site details revised
    • Study title shortened, about 1 word
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2024 to Aug 25, 2023
    • Site details revised
    v4
  3. Notable Start date: Dec 31, 2023 to Dec 31, 2024v3
  4. Notable Start date: Aug 31, 2023 to Dec 31, 2023
    • Primary endpoint revised
    • Primary completion date: Aug 31, 2030 to Jul 31, 2030
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

One-Year Cumulative Probability of All-Cause Death, Heart Transplantation, Heart Failure Hospitalization, or Serious Ventricular Arrhythmia
Timeframe: From the qualifying clinical baseline through 1 year

Secondary (13)

Cumulative Probability of the Composite Clinical Outcome at Short- and Long-Term Follow-Up
Cumulative Probability of All-Cause Death
Cumulative Incidence of Heart Transplantation
Cumulative Incidence of First Heart Failure Hospitalization
At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
Show 8 moreShow less
Number of Heart Failure Hospitalizations per Participant
Cumulative Incidence of First Myocarditis Recurrence
Number of Myocarditis Recurrences per Participant
Change From Baseline in Left Ventricular Ejection Fraction
Percentage of Participants Receiving Mechanical Circulatory Support
Duration of Mechanical Circulatory Support per Episode
Percentage of Participants With Other Arrhythmias
Percentage of Participants With Newly Documented Conduction Abnormalities

Arms and interventions

Retrospective Cohort

Patients of all ages with physician-diagnosed myocarditis identified retrospectively from clinical records covering January 1, 2003, through the protocol amendment date. Available diagnostic, treatment, and outcome data will be collected from existing records. Historical outcomes will be reconstructed for up to five years after the qualifying clinical baseline. Patients may continue the remaining observation period or, after completing the historical period and the applicable consent process, begin a separate five-year prospective observation phase. They retain their original cohort assignment and unique identifier. Historical and newly initiated observation periods are recorded and analyzed separately. Previously stored samples may be used within applicable authorization and ethics approval. Sample availability is not required for inclusion. No treatment is assigned by the study.

Prospective Cohort

Patients of all ages with physician-diagnosed myocarditis enrolled prospectively in the existing FORWARD study or newly recruited through December 31, 2045, excluding those assigned to the retrospective cohort. Previously enrolled patients retain their original identifiers and observation timelines. Clinical data and outcomes are collected at baseline, during hospitalization when applicable, at 1, 3, 6, and 12 months, and annually during years 2 through 5, using routine visits, medical records, or telephone contact. Treatment remains determined by treating clinicians. Optional additional blood or other body fluids may be collected during clinically required sampling, with applicable consent and safety assessment; tissue is limited to material remaining after clinical and pathological needs are met. No research-only puncture is performed. Lack of samples does not affect enrollment or follow-up.

Sites

1 site in 1 country

  • First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, Shaanxi, China